(Q37894095)

24 August 2017

1 reference

title

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive (English)

1 reference

24 August 2017

1 reference

7

Rafael Rosell

1 reference

24 August 2017

0 references

Mariacarmela Santarpia

1

1 reference

24 August 2017

Giuseppe Altavilla

2

1 reference

24 August 2017

Maria F Salazar

3

1 reference

24 August 2017

Ignacio Magri

4

1 reference

24 August 2017

Giuseppe Pettineo

5

1 reference

24 August 2017

Sara Benecchi

6

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Expert Review of Respiratory Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

5

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

413-424

1 reference

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

24 August 2017

cites work

1 reference

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

Targeted therapies for non-small cell lung cancer

21 January 2018

1 reference

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

Impact of EGFR mutation analysis in non-small cell lung cancer.

21 January 2018

1 reference

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab

21 January 2018

1 reference

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

21 January 2018

1 reference

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

21 January 2018

1 reference

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

21 January 2018

1 reference

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

21 January 2018

1 reference

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

21 January 2018

1 reference

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

21 January 2018

1 reference

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

21 January 2018

1 reference

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

21 January 2018

1 reference

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

MicroRNA signatures in human cancers

21 January 2018

1 reference

MicroRNAs and cancer: short RNAs go a long way.

21 January 2018

1 reference

MicroRNA signatures in human ovarian cancer

21 January 2018

1 reference

MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells

21 January 2018

1 reference

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

21 January 2018

1 reference

Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.

21 January 2018

1 reference

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

21 January 2018

1 reference

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERS.11.27

1 reference

24 August 2017

1 reference